TrialProstate cancer and prostatic diseases2025

Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719).

Giulio Francolini et al.PubMed ↗Publisher ↗

No numbers read from the abstract.